217 related articles for article (PubMed ID: 7636535)
1. Interferon alfa-2a and 13-cis-retinoic acid in renal cell carcinoma: antitumor activity in a phase II trial and interactions in vitro.
Motzer RJ; Schwartz L; Law TM; Murphy BA; Hoffman AD; Albino AP; Vlamis V; Nanus DM
J Clin Oncol; 1995 Aug; 13(8):1950-7. PubMed ID: 7636535
[TBL] [Abstract][Full Text] [Related]
2. Phase III trial of interferon alfa-2a with or without 13-cis-retinoic acid for patients with advanced renal cell carcinoma.
Motzer RJ; Murphy BA; Bacik J; Schwartz LH; Nanus DM; Mariani T; Loehrer P; Wilding G; Fairclough DL; Cella D; Mazumdar M
J Clin Oncol; 2000 Aug; 18(16):2972-80. PubMed ID: 10944130
[TBL] [Abstract][Full Text] [Related]
3. Expression of retinoic acid receptor beta in human renal cell carcinomas correlates with sensitivity to the antiproliferative effects of 13-cis-retinoic acid.
Hoffman AD; Engelstein D; Bogenrieder T; Papandreou CN; Steckelman E; Dave A; Motzer RJ; Dmitrovsky E; Albino AP; Nanus DM
Clin Cancer Res; 1996 Jun; 2(6):1077-82. PubMed ID: 9816270
[TBL] [Abstract][Full Text] [Related]
4. Effects of retinoic acid and interferon-gamma on expression of the retinoic acid receptor in mouse renal cell carcinoma.
Hara I; Taguchi I; Miyake H; Hara S; Gotoh A; Kamidono S
Int J Oncol; 2001 Nov; 19(5):959-62. PubMed ID: 11604994
[TBL] [Abstract][Full Text] [Related]
5. Randomized phase II/III trial of interferon Alfa-2a with and without 13-cis-retinoic acid in patients with progressive metastatic renal cell Carcinoma: the European Organisation for Research and Treatment of Cancer Genito-Urinary Tract Cancer Group (EORTC 30951).
Aass N; De Mulder PH; Mickisch GH; Mulders P; van Oosterom AT; van Poppel H; Fossa SD; de Prijck L; Sylvester RJ
J Clin Oncol; 2005 Jun; 23(18):4172-8. PubMed ID: 15961764
[TBL] [Abstract][Full Text] [Related]
6. Up-regulation of retinoic acid receptor beta expression in renal cancers in vivo correlates with response to 13-cis-retinoic acid and interferon-alpha-2a.
Berg WJ; Nanus DM; Leung A; Brown KT; Hutchinson B; Mazumdar M; Xu XC; Lotan R; Reuter VE; Motzer RJ
Clin Cancer Res; 1999 Jul; 5(7):1671-5. PubMed ID: 10430067
[TBL] [Abstract][Full Text] [Related]
7. Interferon alpha-2a and 13-cis-retinoic acid in patients with metastatic renal cell cancer.
Jacobs A; Gold P; Weiden P; Aboulafia D; Rudolph R; Picozzi V; Thompson J
Cancer Invest; 2000; 18(5):417-21. PubMed ID: 10834025
[TBL] [Abstract][Full Text] [Related]
8. Synergistic anti-tumor effect of 13-cRA and IFN-alpha/beta in mouse renal cell carcinoma.
Taguchi I; Hara I; Gohji K; Arakawa S; Kamidono S
Int J Oncol; 1998 Jul; 13(1):145-9. PubMed ID: 9625816
[TBL] [Abstract][Full Text] [Related]
9. Interaction of retinoic acid and interferon in renal cancer cell lines.
Nanus DM; Geng Y; Shen R; Lai HK; Pfeffer SR; Pfeffer LM
J Interferon Cytokine Res; 2000 Sep; 20(9):787-94. PubMed ID: 11032398
[TBL] [Abstract][Full Text] [Related]
10. Multicenter phase II trial of interleukin-2, interferon-alpha, and 13-cis-retinoic acid in patients with metastatic renal-cell carcinoma.
Stadler WM; Kuzel T; Dumas M; Vogelzang NJ
J Clin Oncol; 1998 May; 16(5):1820-5. PubMed ID: 9586896
[TBL] [Abstract][Full Text] [Related]
11. Interferon-alpha-2a with or without 13-cis retinoic acid in patients with progressive, measurable metastatic renal cell carcinoma.
Fosså SD; Mickisch GH; De Mulder PH; Horenblas S; van Oosterom AT; van Poppel H; Fey M; Croles JJ; de Prijck L; Van Glabbeke M
Cancer; 2004 Aug; 101(3):533-40. PubMed ID: 15274066
[TBL] [Abstract][Full Text] [Related]
12. Epigenetic modulation of retinoic acid receptor beta2 by the histone deacetylase inhibitor MS-275 in human renal cell carcinoma.
Wang XF; Qian DZ; Ren M; Kato Y; Wei Y; Zhang L; Fansler Z; Clark D; Nakanishi O; Pili R
Clin Cancer Res; 2005 May; 11(9):3535-42. PubMed ID: 15867257
[TBL] [Abstract][Full Text] [Related]
13. 13-cis retinoic acid and interferon alfa-2a in the treatment of metastatic renal cell carcinoma.
Casali A; Sega FM; Casali M; Serrone L; Terzoli E
J Exp Clin Cancer Res; 1998 Jun; 17(2):227-9. PubMed ID: 9700585
[TBL] [Abstract][Full Text] [Related]
14. [Treatment of 32 cervico-uterine cancer patients with 13-cis-retinoic acid and interferon alpha].
Paredes Espinoza M; Lippman SM; Kavanagh JJ; Delgadillo Madrueño F; Paredes Casillas P; Bañuelos Acosta O; Alvarez Márquez V; Buenrostro Ahued MA; de Alba Ayala I; Arias Castro G
Rev Invest Clin; 1994; 46(2):105-11. PubMed ID: 8052740
[TBL] [Abstract][Full Text] [Related]
15. Combined interferon-alfa, 13-cis-retinoic acid, and alpha-tocopherol in locally advanced head and neck squamous cell carcinoma: novel bioadjuvant phase II trial.
Shin DM; Khuri FR; Murphy B; Garden AS; Clayman G; Francisco M; Liu D; Glisson BS; Ginsberg L; Papadimitrakopoulou V; Myers J; Morrison W; Gillenwater A; Ang KK; Lippman SM; Goepfert H; Hong WK
J Clin Oncol; 2001 Jun; 19(12):3010-7. PubMed ID: 11408495
[TBL] [Abstract][Full Text] [Related]
16. In vitro radiosensitization of human cervical carcinoma cells by combined use of 13-cis-retinoic acid and interferon-alpha2a.
Ryu S; Kim OB; Kim SH; He SQ; Kim JH
Int J Radiat Oncol Biol Phys; 1998 Jul; 41(4):869-73. PubMed ID: 9652851
[TBL] [Abstract][Full Text] [Related]
17. A 2-week pretreatment with 13-cis-retinoic acid + interferon-alpha-2a prior to definitive radiation improves tumor tissue oxygenation in cervical cancers.
Dunst J; Hänsgen G; Krause U; Füchsel G; Köhler U; Becker A
Strahlenther Onkol; 1998 Nov; 174(11):571-4. PubMed ID: 9830438
[TBL] [Abstract][Full Text] [Related]
18. All-trans retinoic acid and interferon-alpha for treatment of human renal cell carcinoma multicellular tumor spheroids.
Rohde D; Brkovic D; Hönig d'Orville I
Urol Int; 2004; 73(1):47-53. PubMed ID: 15263793
[TBL] [Abstract][Full Text] [Related]
19. Oxygenation of cervical cancers during radiotherapy and radiotherapy + cis-retinoic acid/interferon.
Dunst J; Hänsgen G; Lautenschläger C; Füchsel G; Becker A
Int J Radiat Oncol Biol Phys; 1999 Jan; 43(2):367-73. PubMed ID: 10030263
[TBL] [Abstract][Full Text] [Related]
20. Phase I study of subcutaneously administered interleukin-2 in combination with interferon alfa-2a in patients with advanced cancer.
Gause BL; Sznol M; Kopp WC; Janik JE; Smith JW; Steis RG; Urba WJ; Sharfman W; Fenton RG; Creekmore SP; Holmlund J; Conlon KC; VanderMolen LA; Longo DL
J Clin Oncol; 1996 Aug; 14(8):2234-41. PubMed ID: 8708712
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
